Orient Europharma Co Ltd (4120) — Cash Flow Reinvestment Rate

Latest as of June 2025: 44.08x

Orient Europharma Co Ltd (4120) has a Cash Flow Reinvestment Rate of 44.08x as of June 2025, reinvesting NT$1.47 Billion (capex NT$89.03 Million plus investments NT$1.38 Billion) from operating cash flow of NT$33.25 Million. Check 4120 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

44.08x
(Capex + Investments) / Operating CF

Total Reinvested

NT$1.47 Billion
Capex + Investments

Operating Cash Flow

NT$33.25 Million
TWD

Capital Expenditures

NT$89.03 Million
TWD

Orient Europharma Co Ltd Cash Flow Reinvestment Rate (2015–2023)

Historical reinvestment intensity for Orient Europharma Co Ltd across 8 annual periods. Explore investment intensity of Orient Europharma Co Ltd to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Orient Europharma Co Ltd (2015–2023)

Year-by-year capital reinvestment analysis for Orient Europharma Co Ltd. For live market cap and broader valuation context, see 4120 company net worth.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2023 5.44x NT$351.83 Million NT$64.67 Million NT$100.70 Million ▼ -75.1%
2021 21.89x NT$1.70 Billion NT$77.65 Million NT$1.56 Billion ▲ +3647.9%
2020 0.58x NT$355.35 Million NT$608.55 Million NT$232.78 Million ▲ +4.4%
2019 0.56x NT$127.14 Million NT$227.37 Million NT$124.98 Million ▼ -36.0%
2018 0.87x NT$202.21 Million NT$231.31 Million NT$201.61 Million ▲ +9.7%
2017 0.80x NT$478.86 Million NT$601.08 Million NT$367.66 Million ▼ -85.4%
2016 5.47x NT$608.30 Million NT$111.24 Million NT$224.81 Million ▲ +912.9%
2015 0.54x NT$347.66 Million NT$643.97 Million NT$229.54 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow